|Day Low/High||43.52 / 45.93|
|52 Wk Low/High||34.53 / 96.59|
Katherine A. High, M.D., will continue to serve as president and head of R&D
Includes exclusive worldwide rights to adeno-associated viral (AAV) gene therapy targeting the liver
Multi-luminance mobility test (MLMT) was the primary endpoint in the Phase 3 trial for investigational LUXTURNA™ (voretigene neparvovec)
Illumina, Spark Therapeutics and Endo International were among the biotech stock movers in premarket trading on Aug. 2.
Potential for first gene therapy for a genetic disease to be approved in both the U.S. and EU
Data show that 65 percent of participants demonstrated the maximal improvement in the clinical trial's primary endpoint, bilateral multi-luminance mobility testing (MLMT), at year one
Investors in Spark Therapeutics Inc saw new options become available this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new August 18th contracts and identified one put and one call contract of particular interest.
Voretigene neparvovec has the potential to be the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the U.S.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.